Inetetamab triggers cardiotoxicity through its interaction with apoptosis, oxidative stress and autophagy pathways
Abstract Inetetamab, a trastuzumab biosimilar, has obtained approval for the treatment of HER2-positive advanced metastatic breast cancer. Despite studies indicating its cardiotoxic properties, the intricate mechanisms underlying its toxicity remain elusive. In the present study, we demonstrated in...
Saved in:
| Main Authors: | Weiqun Wang, Hongliang Zhang, Yikun Qu, Yue Li, Peng Peng, Chengbo Lu, Xinyue Zhao, Ziteng Cai, Chaonan Peng, Xiaoli Guo, Yuxin Guo, Jie Li, Xuebin Li, Linlin Jia, Guangyuan Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-02125-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting
by: Jian Zhang, et al.
Published: (2025-05-01) -
Cardiotoxicity of Anticancer Drugs
by: I. Maiborodin, et al.
Published: (2025-02-01) -
Carbamazepine Cardiotoxicity
by: J Gordon Millichap
Published: (1993-10-01) -
Investigation of cardiotoxic effects of marbofloxacin
by: Devran Coşkun, et al. -
Trastuzumab and cardiotoxicity
by: Petra Sertić, et al.
Published: (2024-01-01)